Fentanyl Sublingual Spray for Breakthrough Cancer Pain in Patients Receiving Transdermal Fentanyl

References

• Taylor DR . Single-dose fentanyl sublingual spray for breakthrough cancer pain . Clin. Pharmacol.5 , 131 – 141 ( 2013 ).
   PubMedGoogle Scholar
• National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology (NCCN Guidelines®): adult cancer pain . National Comprehensive Cancer Network, Inc. , Fort Washington, PA, USA ( 2014 ). http://oralcancerfoundation.org/treatment/pdf/pain.pdf .
   Google Scholar
• Portenoy RK , HagenNA . Breakthrough pain: definition, prevalence and characteristics . Pain41 ( 3 ), 273 – 281 ( 1990 ).
   PubMed Web of Science ®Google Scholar
• Fine PG , BuschMA . Characterization of breakthrough pain by hospice patients and their caregivers . J. Pain Symptom Manage.16 ( 3 ), 179 – 183 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Portenoy RK , PayneD , JacobsenP . Breakthrough pain: characteristics and impact in patients with cancer pain . Pain81 ( 1–2 ), 129 – 134 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Zeppetella G , O’DohertyCA , CollinsS . Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice . J. Pain Symptom Manage.20 ( 2 ), 87 – 92 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Caraceni A , MartiniC , ZeccaEet al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey . Palliat. Med.18 ( 3 ), 177 – 183 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Hwang SS , ChangVT , KasimisB . Cancer breakthrough pain characteristics and responses to treatment at a VA medical center . Pain101 ( 1–2 ), 55 – 64 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Deandrea S , CorliO , ConsonniD , VillaniW , GrecoMT , ApoloneG . Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature . J. Pain Symptom Manage.47 ( 1 ), 57 – 76 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Portenoy RK , BrunsD , ShoemakerB , ShoemakerSA . Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics . J. Opioid Manag.6 ( 2 ), 97 – 108 ( 2010 ).
   PubMedGoogle Scholar
• Davies A , ZeppetellaG , AndersenSet al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies . Eur. J. Pain15 ( 7 ), 756 – 763 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Burton AW , FilbetM , KnightAD , TayiR , PerelmanM . An analysis of the variability of breakthrough pain intensity in patients with cancer . J Community Support. Oncol.12 ( 3 ), 99 – 103 ( 2014 ).
   Google Scholar
• Prommer E . The role of fentanyl in cancer-related pain . J. Palliat. Med.12 ( 10 ), 947 – 954 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Pereira J , LawlorP , ViganoA , DorganM , BrueraE . Equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing . J. Pain Symptom Manage.22 ( 2 ), 672 – 687 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Kornick CA , Santiago-PalmaJ , MorylN , PayneR , ObbensEA . Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain . Drug Saf.26 ( 13 ), 951 – 973 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Donner B , ZenzM , StrumpfM , RaberM . Long-term treatment of cancer pain with transdermal fentanyl . J. Pain Symptom Manage.15 ( 3 ), 168 – 175 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Davis MP . Fentanyl for breakthrough pain: a systematic review . Expert Rev. Neurother.11 ( 8 ), 1197 – 1216 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Subsys (fentanyl sublingual spray), CII, package insert . INSYS Therapeutics, Inc. , Chandler, AZ, USA ( 2014 ).
   Google Scholar
• Rivera IV , MunozGarrido JC , VelascoPG , Ximenezde Enciso IE , ClavaranaLV . Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain . Adv. Ther.31 ( 1 ), 107 – 117 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Rauck R , ReynoldsL , GeachJet al. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study . Curr. Med. Res. Opin.28 ( 5 ), 859 – 870 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Rauck R , ParikhN , DillahaL , BarkerJ , StearnsL . Patient satisfaction with fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain . Pain Pract.15 ( 6 ), 554 – 563 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Rauck R , BullJ , ParikhN , DillahaL , StearnsL . Effective dose titration of fentanyl sublingual spray in patients with breakthrough cancer pain . Pain Pract. doi:10.1111/papr.12360 ( 2015 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Minkowitz H , BullJ , BrownlowRC , ParikhN , RauckR . Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain . Support Care Cancer doi:10.1007/s00520-015-3056-3 ( 2016 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Harris D , RobinsonJR . Drug delivery via the mucous membranes of the oral cavity . J. Pharm. Sci.81 ( 1 ), 1 – 10 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Stevens RA , GhaziSM . Routes of opioid analgesic therapy in the management of cancer pain . Cancer Control7 ( 2 ), 132 – 141 ( 2000 ).
   PubMedGoogle Scholar
• Nalamachu SR , ParikhN , DillahaL , RauckR . Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose . J. Opioid Manag.10 ( 4 ), 247 – 254 ( 2014 ).
   PubMedGoogle Scholar
• Atkinson MJ , SinhaA , HassSLet al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease . Health Qual. Life Outcomes2 , 12 ( 2004 ).
   PubMedGoogle Scholar
• Parikh N , GoskondaV , ChavanA , DillahaL . Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study . Clin. Ther.35 ( 3 ), 236 – 243 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Parikh N , GoskondaV , ChavanA , DillahaL . Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study . Clin. Drug Investig.33 ( 6 ), 391 – 400 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Nalamachu SR , RauckRL , WallaceMS , HassmanD , HowellJ . Successful dose finding with sublingual fentanyl tablet: combined results from 2 open-label titration studies . Pain Pract.12 ( 6 ), 449 – 456 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Hagen NA , FisherK , VictorinoC , FarrarJT . A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials . J. Palliat. Med.10 ( 1 ), 47 – 55 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Mercadante S , AdileC , CuomoAet al. Fentanyl buccal tablet vs. oral morphine in doses proportional to the basal opioid regimen for the management of breakthrough cancer pain: a randomized, crossover, comparison study . J. Pain Symptom Manage.50 ( 5 ), 579 – 586 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Shimoyama N , GomyoI , TeramotoOet al. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain . Jpn. J. Clin. Oncol.45 ( 2 ), 189 – 196 ( 2015 ).
   PubMed Web of Science ®Google Scholar